Adeno-associated virus (AAV) is
Introduction
Adeno-associated virus (AAV) belongs to the family of the Parvoviridae which are among the smallest and structurally simplest DNA viruses. AAV is a non-enveloped virus of 20 -25 nm diameter and contains a linear, single-stranded DNA genome of 4 680 bases with two inverted terminal repeats of 145 bases each (Srivastava et al., 1983) . The nonstructural rep genes are contained within the left half of the genome and encode four proteins designated Rep78, Rep68, Rep52 and Rep40. The mRNA's for Rep78/68 and Rep52/40 are initiated at two different promoters named p5 and p19 according to their position on the AAV genome map. The structural cap genes are transcribed from a third promoter, p40, and encode the three capsid proteins VP1, VP2 and VP3. Transcripts initiating at each of these three promoters share a common intron and terminate at the same polyadenylation site, and both spliced and unspliced mRNAs can be detected in infected cells (Figure 1 ; Srivastava et al., 1983) . Of the three structural proteins VP3 ist the most abundant and accounts for about 90% of the total virion protein, but at present little is known about the structure of these proteins in the capsid.
AAV is a defective virus that requires a helper virus for productive (lytic) replication. The helper virus can be a member of either the adenovirus or herpes virus family (Atchison et al., 1965; Buller et al., 1981) . In the absence of a helper virus, AAV integrates preferentially into a specific locus on human chromosome 19 (AAVS1) and establishes a latent infection (Berns et al., 1975; Kotin et al., 1990; Samulski et al., 1991; Linden et al., 1996) . Upon infection with a helper virus, the AAV genome is rescued from the host chromosome and a lytic cycle with the formation of progeny AAV is initiated (Berns and Linden, 1995) . Despite the fact that AAV is widespread, no disease has been associated with the virus (Berns and Linden, 1995) .
Recombinant adeno-associated viruses (rAAV) have attracted considerable interest as vectors for gene transfer and gene therapy because they lack all viral genes (Samulski et al., 1989) , are not immunogenic, are able to infect both dividing and quiescent cells, and can give rise to long-lasting gene expression in vivo after a single virus injection (see below). This review briefly summarizes the role of AAV and helper virus genes for AAV replication and gene expression, and describes recent improvements in rAAV vector development that have led to successful preclinical The transcripts for Rep78 and Rep68 are initiated at the p5 promoter, those for Rep52 and Rep40 at the p19 promoter. Messenger RNAs encoding the capsid proteins VP1, VP2 and VP3 are transcribed from the p40 promoter. Introns and coding sequences (hatched) are indicated. VP2 is synthesized from an extended VP3 open reading frame by using an upstream ACG start codon. applications of rAAV for gene therapy in a variety of transgenic, spontaneous and chemically-induced animal models of human disease.
Role of AAV and Helper Virus Proteins for AAV Gene Expression and DNA Replication
Rep78 and Rep68 are involved in AAV DNA replication (Hermonat et al., 1984; Ni et al., 1994) . The inverted terminal repeats of the AAV genome form T-shaped hairpin structures which provide a primer for DNA replication (for a detailed model, see Im and Muzyczka, 1990) . Rep78 and Rep68 recognize and bind to sequences in the hairpin structures (Im and Muzyczka, 1989; McCarty et al., 1994) and nick the viral origin of replication at the terminal resolution site (Im and Muzyczka, 1990) . In addition, Rep78 and Rep68 were shown to possess helicase and ATPase activities (Walker et al., 1997) and to mediate site-specific integration of the AAV DNA into a specific locus on human chromosome 19 by interacting with both viral and human DNA sequences Linden et al., 1996; Surosky et al., 1997) .
The Rep proteins can act as both repressors and transactivators of AAV transcription by regulating the activities of the three viral promoters (Pereira et al., 1997) . In the absence of adenovirus, all Rep proteins have been observed to repress p5 and p19 transcription , and the host factor YY1 binds to a sequence in the AAV p5 promoter and inhibits rep gene transcription (Shi et al., 1991; Lewis et al., 1995) . In the presence of adenovirus, transcriptional repression is relieved. This requires the adenovirus E1A protein (Laughlin et al., 1982) and cis-acting sequences in the AAV promoters McCarty et al., 1991) . By binding to YY1, E1A overcomes YY1-mediated transcriptional repression of p5 and causes increased synthesis of Rep78/68 proteins (Shi et al., 1991; Lewis et al., 1995) . Rep78 and Rep68 in turn act as transactivators of p19 and p40 transcription, which further increases the production of Rep52, Rep40 and the capsid proteins. The two smaller regulatory proteins, Rep52 and Rep40, are required for the accumulation of single-stranded genomes that are packaged into viral particles (Hermonat et al., 1984; Berns and Linden, 1995) . In addition, Rep52 also contains a DNA helicase activity (Smith and Kotin, 1998) and has been shown to bind Rep78/68 in cells (Pereira et al., 1997) .
In addition to E1A, the adenovirus early gene functions E1B (Richardson and Westphal, 1984; Samulski and Shenk, 1988) , E2A (Jay et al., 1981; Janik et al., 1989) , E4 (Richardson and Westphal, 1981; Carter et al., 1983) , and VA RNA (West et al., 1987; Janik et al., 1989) are required for a productive AAV infection. The 55 kDa E1B and the E4orf6 proteins interact to facilitate transportation of viral transcripts to the cytoplasm and are necessary for efficient accumulation of viral mRNAs (Samulski and Shenk, 1988; Huang and Hearing, 1989) . The E2A DNA binding protein and the VA RNAs are mainly required for efficient translation of the AAV capsid mRNAs and to increase the steady-state level of AAV transcripts (West et al., 1987; Janik et al., 1989) .
Interestingly, however, none of the adenovirus-encoded proteins is absolutely essential for AAV DNA replication, since genotoxic stimuli and agents, such as UV irradiation, chemical carcinogens, hydroxyurea or heat shock, can also provide help for AAV replication (Yakinoglu et al., 1988) . This suggests that the helper effect of adenovirus or genotoxic agents involves the activity of host factors to establish a cellular milieu that is permissive for AAV replication and gene expression. Several cellular proteins have been implicated in the control of AAV replication, including the single-stranded DNA binding protein, replication protein A, the proliferating cell nuclear antigen and either DNA polymerase ␦ or ⑀ (Ni et al., 1998) . Depending on the treatment, different molecular pathways may be activated and lead to the formation of either circular or linear concatemerized, transcriptionally active AAV genomes (Sanlioglu et al., 1999) .
Methods for the Preparation of Recombinant Adeno-Associated Viral Vectors
The generation of recombinant adeno-associated viruses (rAAV) without wild-type AAV as a helper virus was first reported in 1989 (Samulski et al., 1989) . A rAAV vector harbouring a neomycin or hygromycin expression cassette flanked by the AAV ITR's was cotransfected into HeLa cells with a plasmid carrying all of the AAV coding regions flanked by the adenovirus terminal repeats, but lacking the AAV ITR's (pAAV/Ad). In addition, the cells were infected with adenovirus to allow for the expression of the adenovirus helper functions. This system generated rAAV particles lacking all viral genes that were able to stably transduce the resistance gene into target cells.
Subsequently, many different AAV helper plasmids were constructed in which the rep or cap genes were expressed from heterologous viral or cellular promoters, in an attempt to increase the production of rAAV particles. In one case, a ten-fold improvement in the packaging efficiency of rAAV was reported when the p5 promoter was replaced by the HIV-1 LTR (Flotte et al., 1995) . However, several other groups observed that increasing Rep78/68 synthesis decreased both the production of capsid proteins and the yield of rAAV, while artificially decreasing the synthesis of Rep78/68 had the opposite effect, suggesting that capsid protein synthesis is the limiting factor in the generation of rAAV (Li et al., 1997; Vincent et al., 1997; Grimm et al., 1998; Ogasawara et al., 1998) .
Several groups described the generation of packaging cell lines for facilitated large scale production of rAAV. HeLa cells carrying integrated copies of rAAV vector and AAV helper functions were shown to produce rAAV upon infection with adenovirus, and in one case titers higher than 10 8 infectious units/ml were achieved (Clark et al., 1995; Tamayose et al., 1996) . Another study reported the In the adenovirus-dependent method, co-transfection of rAAV vector and AAV packaging plasmid followed by infection with helper adenovirus, results in the generation of rAAV in 293 cells (adenovirustransformed cells expressing the adenovirus E1A and E1B genes). In the adenovirus-free method, adenovirus has been replaced by a plasmid expressing the E2A, E4 and VA region of adenovirus-5 under the control of their authentic promoters.
generation of an AAV packaging system based on inducible amplification of integrated AAV vector and helper constructs containing the simian virus 40 (SV40) origin of replication. These cells constitutively expressed the reverse tetracycline transactivator and the SV40 large T antigen under the control of the doxycycline-inducible promoter. Culturing clonal cells in the presence of doxycycline followed by adenovirus infection resulted in AAV vector and helper gene amplification and the production of about 10 4 rAAV particles per cell (Inoue and Russell, 1998 ).
In addition, rAAV produced by this system was shown to be free of detectable replication-competent AAV (Ͻ 1 rcAAV/10 8 vector genomes). Yet another approach was taken by infecting HeLa cells containing an integrated rep/cap plasmid with an E2b-defective adenovirus to induce Rep and Cap expression, followed by infection with an adenovirus carrying the rAAV genome inserted in its E1A region. This method can be easily scaled up and was shown to produce high yields of rAAV free of rcAAV (Gao et al., 1998) . However, a disadvantage of all of these strategies is that adenovirus is produced as a by-product (Figure 2 , left panel). Although rAAV and helper adenovirus can be separated reasonably well by several rounds of CsCl gradient centrifugation and residual adenovirus can be inactivated by heating for 30 minutes at 56°C, this treatment often also reduces the infectious titer of rAAV. Therefore, the most important improvement in the production of rAAV has come from replacing the adenovirus by plasmids that express all the adenoviral functions required for AAV replication and packaging, except those already expressed by the 293 producer cells (Figure 2 , right panel) Matsushita et al., 1998; Grimm et al., 1998; Paterna and Büeler, unpublished) . In addition to completely eliminating adenovirus from rAAV preparations, in one case the adenovirus helper plasmid was reported to increase rAAV yields up to 40-fold over the adenovirus-dependent method when transfected together with an AAV packaging plasmid in which the start codon of Rep 78/68 was mutated to ACG . Most importantly, adenovirus-free rAAV efficiently transduce cells and were shown to result in sustained gene expression in skeletal muscle Matsushita et al., 1998) and brain (Paterna and Büeler, unpublished), demonstrating that no adenovirus genes are absolutely required for transduction by rAAV.
Although AAV vector and packaging plasmids lack homologous sequences (Samulski et al., 1989) , wild typelike AAV particles are generated in almost all systems that use transient transfection. The amount of these contaminants is typically between 0.01% and 1% of all particles , and they are generated by non-homologous recombination (Allen et al., 1997; Wang et al., 1998) . The adenovirus terminal repeats were originally introduced to cause replication of the AAV rep/cap packaging functions (Samulski et al., 1989) in adenovirus-infected cells. However, this did not occur. Recombinant AAV stocks prepared with AAV helper constructs lacking the adenovirus terminal repeats were shown to contain less wild type-like AAV and a much higher proportion of infectious particles relative to total particles Wang et al., 1998) .
The conditions and requirements for cell-free replication and packaging of rAAV are presently being worked out (Ding et al., 1997; Zhou and Muzyczka, 1998) . Although these protocols currently only produce low viral titers (10 3 -10 4 transducing units/ml), they can be considered as an attractive start to develop improved methods for the controlled and reproducible production of rAAVs as therapeutic vectors in a cell-free system.
Factors Influencing Transduction by rAAV
AAV can infect a broad range of cell types of human, nonhuman primate, canine, murine and avian origin. Recently, infection studies with defined mutant CHO cell lines revealed cell surface heparan sulfate proteoglycan (HSPG) as a receptor for AAV type 2 attachment and uptake (Summerford and Samulski, 1998) . Subsequently, two different co-receptors, ␣V␤5 integrin (Summerford et al., 1999) and the receptor for human fibroblast growth factor 1 (FGFR-1) (Qing et al., 1999) were identified. In the first study, AAV particles were shown to bind to immunoprecipitated, membrane-bound ␤5 integrin, and CS1/␤5 cells overexpressing ␤5 integrin internalized AAV labeled with a fluorescent dye at a faster rate than the parental CS-1 cells (Summerford et al., 1999) . In the second study, non-permissive human megakaryocytic leukemia M07e cells, which lack HSPG expression but do express FGFR-1, and human lymphoblastoid Raji cells which lack both HSPG and FGFR-1 expression were used in infection studies with an AAV-lacZ virus. While transfection of murine HSPG cDNA into M07e cells was sufficient to render the cells permissive for AAV transduction, as assessed by flow cytometric analysis of the percentage of ␤-galactosidase expressing cells, expression of both murine HSPG and human FGFR-1 was necessary to render Raji cells permissive for AAV-lacZ, although the overall transduction efficiency (10%) was much lower than for M07e cells expressing both HSPG and FGFR-1 (75%). Moreover, binding of [ 35 S]-labeled AAV to 293 cells and AAV-mediated expression of ␤-galactosidase in 293 cells were inhibited by 50% and 89%, respectively, in the presence of basic FGF (Qing et al., 1999) . Taken together, these results suggest that HSPG serves as the major receptor for AAV attachment, but that additional co-receptors facilitate viral entry and are necessary for substantial AAV-mediated transduction. Although no adenoviral genes are essential for transduction by rAAV Matsushita et al., 1998, Paterna and Büeler, unpublished) , the E4orf6 gene product dramatically increases rAAV-mediated transgene expression in infected cells by stimulating AAV secondstrand DNA synthesis (Ferrari et al., 1996; Fisher et al., 1996) . This finding and the observation that rAAV-mediated transgene expression in vivo increases slowly over a period of several weeks Flannery et al., 1997; Snyder et al., 1997; Song et al., 1998) led to the suggestion that inefficient conversion of the single-stranded rAAV genome into a double-stranded, transcription-competent molecule in the absence of adenovirus E4orf6 may be responsible for the slow rise in rAAV gene expression in animal tissues Snyder et al., 1997) . However, a recent study demonstrated that by three days after rAAV vector delivery, the enhancing effect of adenovirus on transduction of airway epithelial cells was no longer seen, suggesting that within a few days secondstrand synthesis is completed (Teramoto et al., 1998) . This notion was substantiated by following the fate of rAAV DNA in skeletal muscle (Vincent-Lacaze et al., 1999) . The latter work showed that efficient second-strand synthesis in skeletal muscle occurs as early as one day after virus injection, but that most of the original AAV DNA is eliminated within a week after injection. Moreover, the onset of transgene expression correlated well with the formation of high molecular weight head-to-tail concatemers of the rAAV genome (Vincent-Lacaze et al., 1999; Duan et al., 1998) . Taken together, these experiments demonstrate that second-strand synthesis occurs relatively fast even in the absence of adenovirus, but that in addition to this event the generation of high molecular weight structures is crucial for the establishment of stable transgene expression in animal tissues (Vincent-Lacaze et al., 1999) . It remains to be determined whether the concatemers are maintained as episomes or integrate into the host genome.
The cellular single-stranded D-sequence-binding protein (ssD-BP), interacts with the D-sequence of the AAV ITR at the 3Ј end of the AAV genome and was proposed to inhibit AAV second-strand synthesis . Activation of the EGF-receptor tyrosine kinase increases phosphorylation of the ssD-BP and decreases the efficiency of AAV transduction, while adenovirus infection, expression of E4orf6 or treatment with some tyrosine kinase inhibitors cause dephosphorylation of the ssD-BP and increase AAV transduction, suggesting that the phosphorylation state of the ssD-BP is a critical determinant for AAV transduction Mah et al., 1998) . Once the gene for the ssD-BP is identified, it will be interesting to test whether overexpression of non-phosphorylatable ssD-BP (with mutated phosphorylation sites) can increase AAV transduction. However, it is likely that additional cellular genes and proteins are involved in determining the efficiency of AAV transduction, and that the activity of at least some of these may also be regulated by E4orf6 and/or other adenoviral proteins.
In Vivo Gene Expression and Gene Therapy with rAAV
Numerous studies with rAAV encoding reporter and 'therapeutic' genes have demonstrated the utility of this vector system to yield efficient and long-term transgene expression in animals after direct injection of the vector into different tissues of several species, including mouse Murphy et al., 1998) , rat (Kaplitt et al., 1994; McCown et al., 1996) , hamster (Li et al., 1999a) , dog (Herzog et al., 1999; Snyder et al., 1999) , african green monkeys (During et al., 1998a) and baboons . Among the tissues that are most efficiently transduced are skeletal muscles Fisher et al., 1997) , brain (Kaplitt et al., 1994; McCown et al., 1996) , retina (Flannery et al., 1997) , liver Koeberl et al., 1997; Xiao et al., 1998b) and gut lamina propria (During et al., 1998b) . In brain, rAAV is preferentially taken up by neurons but the duration of gene expression in different areas are variable (McCown et al., 1996) . The latter phenomenon has been ascribed to viral promoter down-regulation in some brain areas over time (McCown et al., 1996; Klein et al., 1998) . The transduction efficiency of different tissues correlates well with the level of AAV receptor expression (Summerford and Samulski, 1998) and with the phosphorylation state of the ssD-BP . One of the most attractive features of rAAVs is their low or lacking immunogenicity Fisher et al., 1997; During et al., 1998a; Jooss et al., 1998) . In contrast to all other viral vectors used for gene transfer, rAAVs do not encode any viral proteins that may elicit an immune response, and antibodies generated against AAV capsid proteins do not prevent readministration of the vector . However, in one case antibodies generated against the foreign transgene product (factor IX) were shown to limit gene expression (Herzog et al., 1997) . Moreover, in contrast to recombinant adenoviruses which are highly immunogenic, rAAVs fail to infect dendritic cells, potent antigen presenting cells capable of stimulating antigen-specific primary T cell responses that ultimately lead to the elimination of virus-infected cells and abrogation of transgene expression (Jooss et al., 1998) . The lack of a T cell response against rAAV-infected cells is certainly one of the most important factors contributing to extremely long-lasting or even permanent gene expression after a single virus injection McCown et al., 1996; Snyder et al., 1997) .
Gene Therapy in the Brain
AAV-mediated expression of tyrosine hydroxylase (TH) was shown to improve the behavioral deficits in the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease (Kaplitt et al., 1994) . Subsequently, it was demonstrated that co-expression of both TH and aromatic amino acid decarboxylase (AADC) after transduction of rat striatal neurons with two different rAAVs resulted in higher levels of dopamine synthesis and better behavioral correction than infection with either vector alone (Fan et al., 1998) . In another study, injection of a rAAV encoding the neurotrophic factor GDNF above the substantia nigra significantly protected the dopaminergic cell bodies from retrograde degeneration induced by striatal injection of 6-OHDA (Mandel et al., 1997) . Co-expression of TH and GTP cyclohydrolase 1 (GTPCH1) bilaterally in the striatum of dopamine-deficient mice prevented lethality and resulted in a selective restoration of feeding behavior in these mice (Szczypka et al., 1999) .
Gene Therapy of Inherited Retinopathies
Intraocular injection of a rAAV encoding cGMP phosphodiesterase-␤ (PDE-␤) under the control of a truncated mouse opsin promoter was shown to decrease the loss of photoreceptors and increase the sensitivity to light in the retina of rd mice (Jomary et al., 1997) . Moreover, in a transgenic rat model of autosomal dominant retinitis pigmentosa, subretinally delivered rAAV driving the synthesis of a ribozyme that specifically cleaved the mutant rhodopsin mRNA considerably slowed the rate of photoreceptor degeneration (for at least three months) and improved the electroretinographic response to light, demonstrating functional recovery of photoreceptors in the treated rats (Lewin et al., 1998) .
Gene Therapy of Muscular, Metabolic and Hematopoietic Diseases
Skeletal muscles and liver transduced with rAAV have been used as platforms for the secretion of several factors which are absent or reduced in certain diseases, including factor IX (Wang et al., 1999; Herzog et al., 1999; , ␤-glucuronidase (Daly et al., 1999) , ␣1-antitrypsin (Song et al., 1998) , leptin and erythropoietin (Kessler et al., 1996; . These treatments led to sustained synthesis of therapeutic levels of the corresponding proteins in the serum (Song et al., 1998; Kessler et al., 1996; , and resulted in the correction of the disease phenotype in mouse and dog models of hemophilia B (Wang et al., 1999; Herzog et al., 1999; Snyder et al., 1999) , murine mucopolysaccharidosis type II (Daly et al., 1999) and genetic obesity . In addition, AAV-mediated intramuscular expression of ␦-sarcoglycan led to the restoration of the sarcoglycan complex to the sarcolemma in a hamster model of limb girdle muscular dystrophy (Li et al., 1999a , Greelish et al., 1999 . Finally, transduction of cultured primate CD34 + pluripotent stem cells with an AAV vector encoding ␤-globin, followed by transplantation of infected cells into irradiated autologous rhesus monkeys, resulted in the persistence of multiple cell lineages of vector-transduced progenitor cells for at least 15 months, suggesting that rAAV may be a useful vector for the treatment of hematopoietic disorders (Schimmenti et al., 1998) . The expression levels for some gene products, such as the globins, may need to be within a defined range for therapeutic purposes. Unfortunately, inclusion of a complete locus control region in a rAAV vector is not possible. However, synthetic promoters producing the desired level of transgene expression may be engineered by random assembly of transcriptional control elements in recombinant libraries (Li et al., 1999b) .
AAV Vectors for Regulatable Gene Expression
Long-term and reversible induction of erythropoietin (Epo) secretion and modulation of the hematocrit by tetracycline or doxycycline was described after intramuscular injection in mice of two separate or a single AAV vector encoding the tetracycline transactivator and the Epo gene under the control of a transactivator-responsive promoter (Rendahl et al., 1998; Bohl et al., 1998) . In another system, a mixture of two AAV vectors, one expressing two rapamycin-dependent transcription factor chimeras and one containing the Epo gene under the control of a promoter responsive to the transcription factor, resulted in a 200-fold increase of plasma Epo levels in mice and a rhesus monkey (Ye et al., 1999) . In the rat brain, a dual cassette rAAV vector carrying the GFP reporter gene under the control of the tetracycline-responsive promoter and the tetracycline transactivator caused the reversible supression of GFP fluorescence by the addition of doxycycline to the drinking water (Haberman et al., 1998) .
Retargeted and Site-Specific AAV Vectors
Recently, rAAV has been retargeted to non-permissive megakaryocytic cells by means of a bispecific antibody recognizing the AAV capsid and the megakaryocyte-specific cell-surface integrin ␣IIb␤3, resulting in the successful infection of otherwise non-permissive cells . In a different approach, inclusion of a chimeric single chain antibody-rAAV capsid protein within a rAAV virion significantly increased the infectivity of the rAAV for a CD34 + human myoleukemia cell line which is normally refractory to rAAV transduction . The elimination of the rep gene in rAAV results in a lack of site-specific integration of rAAV vectors (Ponnazhagan et al., 1997) . Random integration of rAAV may entail the risk for deleterious insertional mutagenesis of endogenous genes, although the chances for this are considered to be low. Firstly, numerous animal experiments and clinical trials in humans, in which cells genetically modified by recombinant retroviruses were reimplanted into the organism, have shown that insertional mutagenesis does not pose a serious problem. Moreover, most genes are present in two copies, making it unlikely that both copies are inactivated, and studies with knockout mice have shown that the vast majority of gene deletions cause no phenotype in the heterozygous state. Nevertheless, a certain low risk can not be excluded. In an attempt to re-direct integration of rAAV into the natural genomic locus of wildtype AAV (AAVS1), hybrid adenovirus/AAV or baculovirus/AAV (Palombo et al., 1998) vectors which contain a rAAV genome and, at a separate position, the gene for Rep78, were constructed. These vectors were used as carriers to introduce the rAAV genome into cells, and transient expression of Rep78 was shown to mediate site-specific integration of the rAAV genomes into AAVS1, although the specificity was not absolute. In addition, transgenic mice and rats which contain a human genomic DNA fragment encompassing AAVS1 were generated to study site-specific integration of AAV in vivo (Rizzuto et al., 1999) . These developments may ultimately lead to rAAV vectors that, like wild-type AAV, preferentially integrate into AAVS1.
Conclusions
Over the past few years, the increasing knowledge about the importance of the balance between Rep and Cap protein synthesis for efficient rAAV packaging, and the development of adenovirus-free production systems as well as of strategies to eliminate the generation of replicationcompetent AAV, have led to substantially improved rAAV stocks with respect to both purity and infectious titers. In parallel, numerous applications of rAAVs as therapeutic agents have demonstrated the utility of this vector system for long-lasting genetic modification and gene therapy in preclinical models of human disease. With the ongoing efforts of many groups working in this field, there is hope that rAAVs will realize therapeutic benefits in the clinic within the next few years to come.
